Galapagos (GB:0JXZ)
LSE:0JXZ
Want to see GB:0JXZ full AI Analyst Report?
0JXZ Stock Chart & Stats
€24.70
€0.10(0.38%)
At close: 4:00 PM EST
€24.70
€0.10(0.38%)
Day’s Range― - ―
52-Week Range€21.62 - €32.70
Previous CloseN/A
Volume42.14K
Average Volume (3M)9.16K
Market Cap
€1.62B
Enterprise Value€1.55B
Total Cash (Recent Filing)€3.00B
Total Debt (Recent Filing)€12.10M
Price to Earnings (P/E)5.7
Beta0.61
Next Earnings
May 06, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.87
Shares Outstanding65,897,070
10 Day Avg. Volume4,733
30 Day Avg. Volume9,162
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.57
Price to Sales (P/S)1.66
P/FCF Ratio-8.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€25.85Price Target Upside4.66% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering4
EPS Forecast (FY)-2.08
Revenue Forecast (FY)€81.19M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and large equity provide durable financial flexibility, lowering refinancing and covenant risk. This supports R&D investment and partnership negotiation power for 2-6 months and beyond, allowing the company to absorb cash burn or time licensing milestones without urgent capital raises.
Revenue & Profit ReboundA large, recent increase in revenue and positive net income shows meaningful operational progress and commercial traction. Sustained higher revenues can fund pipeline advancement and partnership terms, improving medium-term earnings quality if the company preserves margin and converts sales into consistent operating cash flow.
Diversified Revenue ModelA business model mixing collaboration/licensing milestones and retained product sales spreads revenue concentration risk. Durable partner-funded R&D and milestone streams can provide non-dilutive funding and reduce reliance on single-product launch timing, improving medium-term funding predictability.
Bears Say
Weak Cash GenerationConsistently negative operating and free cash flow means core operations do not self-fund, increasing reliance on cash reserves, partner payments, or financings. Over 2-6 months this raises execution risk for R&D and commercialization if milestone timing shifts or cash burn remains elevated.
Earnings VolatilityA history of swings between losses and gains indicates earnings may depend on lumpy milestone or one-off items rather than stable product cash flow. This structural volatility complicates forecasting, budgeting and long-term planning for sustained investment or predictable shareholder returns.
Declining Asset BaseShrinking total assets can signal reduced scale of operations or asset sales to cover cash needs. Over a medium-term horizon this may constrain capacity to expand R&D or commercial footprints and reduce collateral for financing, weakening strategic optionality if cash burn persists.
Galapagos News
0JXZ FAQ
What was Galapagos’s price range in the past 12 months?
Galapagos lowest share price was €21.62 and its highest was €32.70 in the past 12 months.
What is Galapagos’s market cap?
Galapagos’s market cap is €1.62B.
When is Galapagos’s upcoming earnings report date?
Galapagos’s upcoming earnings report date is May 06, 2026 which is in 16 days.
How were Galapagos’s earnings last quarter?
Galapagos released its earnings results on Feb 23, 2026. The company reported €11.87 earnings per share for the quarter, beating the consensus estimate of -€0.11 by €11.98.
Is Galapagos overvalued?
According to Wall Street analysts Galapagos’s price is currently Undervalued.
Does Galapagos pay dividends?
Galapagos does not currently pay dividends.
What is Galapagos’s EPS estimate?
Galapagos’s EPS estimate is -0.82.
How many shares outstanding does Galapagos have?
Galapagos has 65,897,070 shares outstanding.
What happened to Galapagos’s price movement after its last earnings report?
Galapagos reported an EPS of €11.87 in its last earnings report, beating expectations of -€0.11. Following the earnings report the stock price went up 5.934%.
Which hedge fund is a major shareholder of Galapagos?
Currently, no hedge funds are holding shares in GB:0JXZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galapagos
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
0JXZ Stock 12 Month Forecast
Average Price Target
€25.85
▲(4.66% Upside)
Technical Analysis
Options Prices
Currently, No data available
---